Home  »  Morning Brief   »  BioCryst Pharmaceuticals, Inc. (BCRX) Stock Nose-D...

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Nose-Diving in Regular Market, Here’s Why

BioCryst Pharmaceuticals, Inc. (BCRX), a biotechnology company, is trading at $11.64 in the current market after plunging 34.90% since the start of the trading session.

BCRX Paused Enrolment

BCRX stock started to dive following the pause in enrolment for BCX9930 Clinical Trials. Hours ago, the company has announced that it has paused the enrolment in the clinical trials for BCX9930 as it is investigating the high levels of serum creatinine which is seen in some of the patients. However, the patients currently enrolled in the study would continue to take the drug.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.


Biotech Sector in Doldrums

Biotech stocks are depicting one of the worst stock market performances in several years. The rising inflation, hike in interest rates, and setbacks in scientific developments are proving to be a big hindrance to the growth of the biotech sector. Immediately after the onset of the pandemic, the biotech sector saw unprecedented growth as the medical industry was in a race to develop new vaccines for countering COVID-19. However, the most recent developments have seen the boom turn into a bearish spell.

BCRX Stock Having Insider Selling

Market observers are of the view that insider selling in BCRX stock has been on a significantly higher side during the last three months. During the period, insiders sold more than $0.5 million worth of the shares, while the share purchase remained on a negligible side. The huge volume of insider trading is pointing toward an upcoming weakness for the stock, but it hasn’t had any impact up till now.

Final Remarks

BCRX stock hasn’t been able to portray a solid performance in the recent past. Looking ahead, it seems that the fundamentals are not that strong for the company at the moment. Hence, it could face trouble in near future. However, biotech stocks could and should not be voted out merely based on the current outlook as medicinal products developed by them could instantly change their fortunes.

Leave a Comment

Your email address will not be published.

Autodesk Inc. (ADSK) Just Got Our Attention

Autodesk Inc. (NASDAQ:ADSK) went up by 0.66% from its latest closing price compared to the recent 1-year high of $335.48. The company’s stock price has